event details

BridgeBio Pharma shares topline 30-month results from Phase 3 ATTRibute-CM study

07.17.2023 at 8:00 AM EDT

Click here for webcast

Print Page

Email Alerts

RSS Feeds

Contact IR

join our investor mailing list

Stay informed on everything that is happening at BridgeBio Investor Relations.

Required fields denoted by an asterisk ().

Alert type
Quote
SEC Filing
Event
News
Weekly Summary

Follow us on LinkedIn, Twitter, Facebook, and YouTube for the latest news.

© 2024 BridgeBio Inc. All rights reserved. | For Investors | careers | terms of use | privacy policy | cookies notice | us expanded access policy | contact us | sms policy

3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 | info@bridgebio.com | MAT-AS—0001